A Phase II Study of Bortezomib (VELCADE) in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL).

Trial Profile

A Phase II Study of Bortezomib (VELCADE) in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL).

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Aug 2012 Additional lead trial centre added as reported by ClinicalTrials.gov.
    • 18 Feb 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 18 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top